STEAP1 as a Radioligand Therapy Target
STEAP1, STEAP family member 1, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, STEAP1 staining is highest in lung cancer (27% of samples positive), prostate cancer (11% of samples positive) and gastric cancer (10% of samples positive). Clinical status: Clinical-stage (up to phase 1, any modality), with 1 active clinical trial.
Is STEAP1 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ⚠️ Tumor expression: Medium IHC staining in lung cancer, 27% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: Clinical-stage (up to phase 1, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
STEAP1 expression in cancer
Protein expression of STEAP1 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Lung Cancer | 0.21 | Medium | 27% |
| Prostate Cancer | 0.04 | Low | 11% |
| Gastric Cancer | 0.03 | Low | 10% |
Not detected by IHC in: skin cancer, colorectal cancer, head and neck cancer, ovarian cancer, lymphoma, breast cancer, melanoma, kidney cancer, thyroid cancer, bladder cancer, neuroendocrine tumors, cervical cancer, pancreatic cancer, testicular cancer, endometrial cancer, glioma, liver cancer.
Is STEAP1 internalized?
Nuclens has not yet extracted internalization evidence for STEAP1. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
STEAP1 clinical trials
Clinical-stage (up to phase 1, any modality). 1 active trial reference STEAP1 (ClinicalTrials.gov, accessed 2026-08-17).
STEAP1 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See STEAP1 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
STEAP1 gene essentiality (DepMap)
CRISPR knockout effect across 1140 cancer cell lines: 0.12 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related lung cancer radioligand targets
EGFR · HER3 (ERBB3) · c-MET (MET) · EPCAM · CEA (CEACAM5) · STEAP2 · B7-H3 (CD276) · Mesothelin (MSLN)
See all radioligand therapy targets in lung cancer.
See how STEAP1 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.